Gadolinium news

All news on Gadolinium: plants, production capacities, investments and involved companies.

27 August 2025

FDA Reviews Bayer's Gadoquatrane Application

Gadoquatrane, a low-dose MRI contrast agent, shows positive Phase III results. It's under review in the U.S., Japan, and EU for use in adults and children, including neonates.
10 July 2025

Bayer Seeks EU Approval for Gadoquatrane

Gadoquatrane, a low-dose MRI contrast agent, shows positive Phase III results. EU approval could reduce gadolinium exposure by 60% compared to current standards.

Who will be producing Gadolinium in the future?

Find out with chemXplore Alpha

Learn more